Medical monitor support and advice for FLU-v phase IIb study for influenza
Each year, influenza affects up to 5 million people worldwide and leads to an estimated 650,000 deaths. Currently, the most effective available treatment is an annual vaccination with inactivated and attenuated influenza virus. With the annual challenge of new strains, the efficacy of vaccines can be affected, and vaccine availability is often limited. There are a […]
Dr Bryan Murray joins Clinical and Medical Affairs Team
Dr Bryan Murray has joined Boyds as a Pharmaceutical Physician within the growing Clinical and Medical Affairs team. Bryan Murray is an experienced trials physician with over 10 years’ experience working on various clinical phase studies initially as a principal investigator (PI) and more latterly as a medical monitor and clinical research physician. Bryan qualified […]
Regulatory affairs team bolstered with appointment of Submissions Compliance and Quality Manager
Navila Rehman has joined Boyds as Submissions Compliance and Quality Manager within the regulatory affairs team. Navila brings over 20 years’ experience in the pharmaceutical industry with a primary focus on quality systems and regulatory operations. Qualified with a BSc in Pharmaceutical Management, Navila has held a number of roles including Quality Systems Manager at […]
Virtual drug development
Nick Meyers, VP of Product Development at Boyds, spoke at a recent MarketsAndMarkets event on pragmatic drug development solutions for virtual and semi-virtual sponsors. In his talk, Nick discussed the pros and cons of taking this virtual drug development route to developing medicines for patient benefit. He also discussed how Boyds can help virtual companies […]
IBD & Tea: building trust in new treatments
Professor Alan Boyd took part in ‘ IBD & Tea’, a recent online debate focused on building trust in new treatments and understanding clinical trials, conducted as part of the New Deal project. In Europe, over two million people are affected by ulcerative colitis or Crohn’s disease, conditions that are characterised by an inflammation of the […]
Nanomedicine comes of age
European researchers take nanotech-based therapies (nanomedicine) from the lab to the clinic With more than 50 nanomedicine formulations already in the market and over 400 currently in clinical trials1, regulation for this class of medicines is set to become more streamlined. Several European research and innovation projects are developing nanomedicines in diverse areas with unmet […]
Victoria Marsh joins the team as Director of Regulatory Affairs
Responding to sustained growth in demand for our Regulatory Services, Boyds has appointed Dr Victoria Marsh, a specialist in molecular biology and protein biochemistry, as Director of Regulatory Affairs in our Regulatory Affairs team. Victoria Marsh has extensive regulatory experience across the full product lifecycle from Phase I clinical trials through to licence maintenance for […]
Boyds assists researchers and developers on COVID-19 projects
Boyds has a wealth of experience in early development and translational medicine and we are already supporting a number of vital COVID-19 projects. As this coronavirus is new, we need to pool resources and draw on expertise across the industry to work quickly and efficiently and help find vaccines and medicines that will protect patients […]
Dr Kim Champion joins the team as Regulatory Affairs Manager
We are delighted to welcome Dr Kim Champion to the Boyds team as Regulatory Affairs Manager. With extensive experience in the Clinical Operations sphere, Kim will help prepare regulatory documentation and provide operational support to sponsors in all stages of drug development. After moving from Switzerland to England in 1990, Kim began her career as […]
Professor Alan Boyd tells his story on The Cat 107.9FM
Following Boyds’ success in the South Cheshire Chamber of Commerce Awards, when the company won Business of the Year (under 25 employees), Professor Alan Boyd has been sharing his career journey, insights into the development of cell and gene therapies for patient benefit, as well as the story behind the growth of Boyds. The radio […]
